To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Accelerating Medicines Partnership – Alzheimer's Disease Phase 2

The Accelerating Medicines Partnership Alzheimer’s Disease (AMP AD Phase 2)  is a new precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s Disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s Disease. 

Plasticity and Mechanisms of Cognitive Remediation in Older Adults

Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.

Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges and to generate the epidemiologic basis for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The program will measure a panel of biomarkers in almost 30,000 individuals in a national study. The project will provide key reference data regarding novel biomarkers for cardiovascular risk stratification and inform U.S. clinical and laboratory guidelines.